Latham & Watkins Advises on Catalyst’s US$150 Million Offering of Common Stock

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases, has announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of US$15 per share, for total gross proceeds of US$150 million, before deducting underwriting discounts and expenses payable by Catalyst. Catalyst has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts. The offering is expected to close on or about January 9, 2024, subject to customary closing conditions. All of the shares in the offering are being sold by Catalyst.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Shawn Quinn, Matthew Schlanger, and Vanessa Hillabrand.